✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Sun Pharma Advanced Research Company Ltd.

SPARC

Market Cap
₹7,738 Cr.
P/E
4.98

Sun Pharma Advanced Research Company Ltd.

  • Sun Pharma Adv. Res
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
  • TJI Pharma - Small Cap

FAQs on Sun Pharma Advanced Research Company Ltd. Shareprice

Sun Pharma Adv. Res has given lower returns compared to its competitors.
Sun Pharma Adv. Res has grown at ~-7.27% over the last 8yrs while peers have grown at a median rate of 2.47%

Yes, Sun Pharma Adv. Res is expensive.
Latest PE of Sun Pharma Adv. Res is 4.98, while 3 year average PE is 0.09.
Also latest EV/EBITDA of Sun Pharma Adv. Res is 5.19 while 3yr average is 0.08.

View FAQ's On Business

Growth Table

  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Balance Sheet

  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Cash Flow

  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Quarterly Results

  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Sun Pharma Advanced Research Company Ltd. Financials

Balance sheet of Sun Pharma Adv. Res is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of Sun Pharma Adv. Res is increasing.
Latest net debt of Sun Pharma Adv. Res is ₹555 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹254 Crs.

Yes, profit is increasing.
The profit of Sun Pharma Adv. Res is ₹1,553 Crs for TTM, -₹342.51 Crs for Mar 2025 and -₹387.21 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Sun Pharma Adv. Res latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech